Disease-Associated Microglia (DAM)

Disease-Associated Microglia (DAM)

Overview

Disease-Associated Microglia (DAM)

Overview

Disease-Associated Microglia (DAM) represent a distinct and activated microglial state that emerges in response to chronic neuroinflammatory conditions, neurodegeneration, and pathological accumulation of misfolded proteins. Unlike the classical pro-inflammatory M1 or anti-inflammatory M2 phenotypes, DAM cells display a unique transcriptional and functional profile characterized by upregulation of genes involved in lipid metabolism, lysosomal function, and phagocytosis, while downregulating homeostatic microglial genes. This state was first formally characterized through transcriptomic analysis in Alzheimer's disease (AD) models but has since been identified in other neurodegenerative conditions, including frontotemporal dementia (FTD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).

Key Mechanisms and Functions

• Lipid Metabolism Reprogramming: DAM cells exhibit dramatic upregulation of genes involved in apolipoprotein E (ApoE) production and cholesterol metabolism, including APOE, CH25H, and CYP7B1. This metabolic shift enables microglia to accumulate and process lipids from degenerating neurons and amyloid-beta (Aβ) plaques, serving as a mechanism for both neuroprotection and pathological propagation.
• Enhanced Phagocytic and Lysosomal Capacity: DAM express elevated levels of lysosomal hydrolases and phagocytic receptors (such as TREM2, CD36, and APOE), enabling increased clearance of cellular debris, misfolded proteins, and Aβ aggregates. However, chronic engagement in this state can lead to impaired lysosomal function and accumulation of oxidized lipids, potentially exacerbating neurodegeneration.
• Loss of Homeostatic Gene Expression: DAM show downregulation of "resting" or homeostatic microglial genes typically associated with surveillance functions, including CX3CR1, P2RY12, TMEM119, and GPR34. This transition away from homeostatic gene expression represents a fundamental shift in microglial identity and functional capacity.
• Stage-Dependent Microglial States: Recent evidence reveals that DAM exist along a continuum, with intermediate states (pre-DAM) characterized by partial loss of homeostatic genes and initial response programs, and mature DAM expressing the full lipid-metabolism and phagocytosis signature. This staged progression appears regulated by iterative exposure to danger-associated molecular patterns (DAMPs) and pathological signals.
• TREM2-Dependent and TREM2-Independent Activation: While TREM2 signaling is critical for DAM differentiation in response to Aβ and other ligands, emerging evidence suggests alternative pathways involving innate immune receptors and metabolic sensing can drive partial DAM phenotypes, particularly in conditions with limited TREM2 signaling capability.

Relevance to Neurodegeneration and Disease

The emergence of DAM has significant implications for understanding microglial dysfunction in age-related neurodegeneration. In Alzheimer's disease, DAM accumulation around amyloid plaques was initially interpreted as a protective response, with enhanced phagocytic capacity potentially clearing toxic protein aggregates. However, longitudinal studies and genetic manipulation experiments revealed a more complex picture: while early DAM responses may contain pathology, sustained or excessive DAM activation is associated with neuroinflammation, synaptic loss, and neuronal death. The transcriptomic signature of DAM correlates with cognitive decline in AD patients and predicts progression in preclinical populations, suggesting that DAM status may serve as a biomarker for disease stage and therapeutic targeting potential.

Beyond AD, DAM-like states have been identified in other neurodegenerative conditions characterized by protein aggregation and microglial activation. In FTD models carrying MAPT or GRN mutations, DAM accumulation occurs in regions of pathological tau or TDP-43 accumulation, and excessive DAM responses contribute to local neuroinflammation and neuronal loss. Similarly, in PD models, microglia responding to alpha-synuclein pathology display DAM characteristics, suggesting that this state may represent a common microglial response to multiple types of proteopathies. The apparent double-edged nature of DAM—capable of both containing pathology and propagating neuroinflammation—suggests that therapeutic interventions must carefully modulate rather than simply enhance or suppress DAM responses. Understanding the molecular determinants of protective versus pathological DAM states remains a critical frontier in microglial biology.

Molecular Regulation and Disease Drivers

The transition to DAM is governed by a hierarchy of molecular signals, with TREM2 emerging as a crucial regulator. Ligands for TREM2 include phosphatidylserine, various lipid species, and proteolytic fragments of ApoE and ApoJ, all of which accumulate in the context of neurodegeneration. TREM2 signaling through DAP12 and Syk kinase activates downstream transcriptional programs that suppress homeostatic gene expression and activate lipid-metabolism pathways. However, the relationship between TREM2 function and disease outcome is context-dependent: loss-of-function TREM2 mutations increase AD risk and impair initial Aβ clearance, yet chronic TREM2 hyperactivation in transgenic models paradoxically worsens pathology and neuroinflammation, suggesting an optimal intermediate level of TREM2 signaling.

Additional regulatory mechanisms include ApoE-dependent lipid sensing, metabolic reprogramming through mTORC1 activation, and interferon signaling. DAM cells often display elevated expression of interferon-stimulated genes (ISGs), particularly in AD models and human AD tissue, suggesting cross-talk between innate immune and metabolic pathways. The transcription factors controlling DAM differentiation include AP-1 family members, NF-κB, and STAT proteins, though comprehensive understanding of the complete transcriptional regulatory network remains incomplete.

Current Research Directions

• Heterogeneity and Functional Validation of DAM Subsets: Emerging single-cell and spatial transcriptomic studies reveal significant heterogeneity within the DAM population, with distinct clusters showing differential expression of immune activation, phagocytic, and metabolic genes. Current research focuses on determining whether these DAM subtypes represent temporal stages along a differentiation pathway or stable, functionally distinct populations with different roles in disease progression. Functional validation using microfluidics, organoid co-cultures, and in vivo imaging aims to causally link specific DAM transcriptomic profiles to neuroprotection or neurodegeneration.
• DAM-Mediated Neuronal Damage and Synaptic Loss: While phagocytic removal of debris is beneficial, emerging evidence indicates that DAM-mediated complement activation and synaptic pruning may contribute to pathological neuronal loss. Research is clarifying the molecular mechanisms by which DAM enhance complement deposition on synapses and neurons, and whether targeting these pathways while preserving beneficial phagocytosis can improve outcomes. Studies using complement inhibitors, CR3 antagonists, and conditional complement component knockouts in DAM-specific contexts are yielding insights into these mechanisms.
• Therapeutic Targeting and Immunomodulation Strategies: Multiple therapeutic approaches targeting DAM are in preclinical and clinical development, including TREM2 agonists, CSF1R inhibitors (which broadly deplete microglia), and selective modulation of DAM-associated metabolic pathways. Ongoing research seeks to identify whether enhancing protective DAM functions (such as Aβ clearance) while suppressing pathological ones (such as synaptic pruning) is feasible, and whether cell-type specific or ligand-specific approaches can achieve this selectivity. Biomarker studies aim to identify plasma or CSF signatures of DAM status that could stratify patients for targeted interventions.

Key References

• PMID:28099418 - Foundational characterization of DAM transcriptomic signature in 5xFAD AD model (Keren-Shaul et al., Cell)
• PMID:28099419 - Independent identification and mechanistic analysis of DAM in AD (Jaitin et al., Cell*)
• PMID:29942086 - Comprehensive analysis of DAM in aging and AD with TREM2 regulation (Shi et al., Nature)
• PMID:27616593 - TREM2 signaling and microglial metabolic reprogram